Corza Medical Signs Definitive Agreement to Acquire Takeda's TachoSil Manufacturing OperationsGlobeNewsWire • 04/26/23
Celiac Disease Foundation, Takeda Announce Early Career Research Award in Celiac DiseaseBusiness Wire • 04/25/23
Takeda Receives FDA Approval to Expand the Use of HYQVIA® to Treat Primary Immunodeficiency in ChildrenBusiness Wire • 04/11/23
Takeda Announces New U.S. Corporate Social Responsibility (CSR) Program PartnersBusiness Wire • 04/03/23
Takeda Announces Results From Phase 4 Vedolizumab Study in Patients With Chronic Pouchitis Published in New England Journal of MedicineBusiness Wire • 03/30/23
InvoX Pharma's F-star Announces Licence Agreement With Takeda for Second Novel Next-Generation Immuno-Oncology Bispecific AntibodyBusiness Wire • 03/22/23
Phase 2b Clinical Trial Results for TYK2 Inhibitor Presented at American Academy of Dermatology Annual MeetingBusiness Wire • 03/20/23
Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque PsoriasisBusiness Wire • 03/18/23
Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)Business Wire • 02/18/23
Nimbus Therapeutics Announces Closing of Takeda's Acquisition of TYK2 SubsidiaryBusiness Wire • 02/08/23
U.S. FDA Approves Takeda's TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and OlderBusiness Wire • 02/03/23
Takeda Reinforces Long-term Growth Through Pipeline Advancement and Two Targeted Acquisitions; Delivers Another Strong Quarter in FY2022 Q3Business Wire • 02/02/23
Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED's Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase InhibitorBusiness Wire • 01/23/23